Kariya Pharmaceuticals
The startup develops neurodegenerative drugs that utilize dual incretin receptor agonists to slow the progression of Parkinson's and Alzheimer's diseases. By targeting specific pathways involved in neurodegeneration, the company aims to improve patient outcomes and enhance quality of life for those affected by these conditions.
- Biotechnology
Updated 5 months ago
Funding
Raised to date
$3MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops neurodegenerative drugs that utilize dual incretin receptor agonists to slow the progression of Parkinson's and Alzheimer's diseases. By targeting specific pathways involved in neurodegeneration, the company aims to improve patient outcomes and enhance quality of life for those affected by these conditions.